Jonathan S. Berek, MD, MMS

Gynecologic oncologist

Laurie Kraus Lacob Professor
Chair, Department of Obstetrics and Gynecology

Gynecologic Cancer Program

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6004
Learn More About the Clinic Getting Here Make An Appointment

Women's Cancer Center

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6004
Learn More About the Clinic Getting Here Make An Appointment

Gynecology Clinic

  • 900 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-725-6079
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Medical Education: Johns Hopkins University School of Medicine (1973) MD

Residency: Harvard Medical School Brigham and Women's Hospital (1979) MA

Internship: Harvard Medical School Brigham and Women's Hospital (1976) MA

Fellowship: UCLA - School of Medicine (1981) CA

Biomedical Sciences, Brown University, MMS (1973)

Board Certification: Gynecologic Oncology, American Board of Obstetrics and Gynecology (1983)

Board Certification: Obstetrics and Gynecology, American Board of Obstetrics and Gynecology (1982)

Administrative Appointments

Laurie Kraus Lacob Professor, Stanford (2012 - Present)

Chair, Department of Obstetrics and Gynecology, Stanford University School of Medicine (2005 - Present)

Director, Stanford Women's Cancer Center, Stanford Cancer Institute (2008 - Present)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study
Sabbatini, P., Harter, P., Scambia, G., Sehouli, J., Meier, W., & Pfisterer, J. (2013). Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study. JOURNAL OF CLINICAL ONCOLOGY, 31(12), 1554-1561.

Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study.
Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., & Manson, J. E. (2013). Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstetrics and gynecology, 121(4), 709-16.

Cancer of the ovary, fallopian tube, and peritoneum
Berek, J. S., Crum, C., & Friedlander, M. (2012). Cancer of the ovary, fallopian tube, and peritoneum. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 119, S118-S129.

FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage
Chung, Y. M., Park, S.-H., Tsai, W.-B., Wang, S.-Y., Ikeda, M.-A., & Hu, M. Ct. (2012). FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. NATURE COMMUNICATIONS, 3.

Current Management of Vulvar Cancer
Fuh, K. C., & Berek, J. S. (2012). Current Management of Vulvar Cancer. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 26(1), 45-?.

Personalizing CA125 Levels for Ovarian Cancer Screening
Dorigo, O., & Berek, J. S. (2011). Personalizing CA125 Levels for Ovarian Cancer Screening. CANCER PREVENTION RESEARCH, 4(9), 1356-1359.

Strategies and Goals: The Future of the International Gynecologic Cancer Society IGCS Presidential Address
Berek, J. S. (2010). Strategies and Goals: The Future of the International Gynecologic Cancer Society IGCS Presidential Address. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 20(9), 1434-1439.

Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy Recommendations Based on Risk of Ovarian Cancer
Berek, J. S., Chalas, E., Edelson, M., Moore, D. H., Burke, W. M., & Berchuck, A. (2010). Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy Recommendations Based on Risk of Ovarian Cancer. OBSTETRICS AND GYNECOLOGY, 116(3), 733-743.

Lymph Node-Positive Stage IIIC Ovarian Cancer A Separate Entity?
Berek, J. S. (2009). Lymph Node-Positive Stage IIIC Ovarian Cancer A Separate Entity?. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 19, S18-S20.

Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses' Health Study
Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., & Manson, Ja. E. (2009). Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses' Health Study. OBSTETRICS AND GYNECOLOGY, 113(5), 1027-1037.

Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer The Gynecologic Oncology Group Experience
Markman, M., Brady, M., Hutson, A., & Berek, J. S. (2009). Survival After Second-Line Intraperitoneal Therapy for the Treatment of Epithelial Ovarian Cancer The Gynecologic Oncology Group Experience. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 19(2), 223-229.

Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
Berek, J., Taylor, P., McGuire, W., Smith, L. M., Schultes, B., & Nicodemus, C. F. (2009). Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer. JOURNAL OF CLINICAL ONCOLOGY, 27(3), 418-425.

HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review
Karam, A., Berek, J. S., Stenson, A., Rao, J., & Dorigo, O. (2008). HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review. GYNECOLOGIC ONCOLOGY, 111(3), 568-571.

Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007
Ashworth, A., Balkwill, F., Bast, R. C., Berek, J. S., Kaye, A., & Workman, P. (2008). Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. GYNECOLOGIC ONCOLOGY, 108(3), 652-657.

Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer
Chan, J. K., Kapp, D. S., Cheung, M. K., Shin, J. Y., Stieglitz, D., & Guo, H. (2008). Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 198(2).

Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths
Ueda, S. M., Kapp, D. S., Cheung, M. K., Shin, J. Y., Osann, K., & Chan, J. K. (2008). Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 198(2).

CA125 velocity at relapse is a highly significant predictor of survival post relapse: Results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer
Berek, J. S., Taylor, P. T., & Nicodemus, C. F. (2008). CA125 velocity at relapse is a highly significant predictor of survival post relapse: Results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. JOURNAL OF IMMUNOTHERAPY, 31(2), 207-214.

Elective oophorectomy in the gynecological patient: when is it desirable?
Parker, W. H., Shoupe, D., Broder, M. S., Liu, Z., Farquhar, C., & Berek, J. S. (2007). Elective oophorectomy in the gynecological patient: when is it desirable?. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 19(4), 350-354.

Vulvar melanoma - A multivariable analysis of 644 patients
Sugiyama, V. E., Chan, J. K., Shin, J. Y., Berek, J. S., Osann, K., & Kapp, D. S. (2007). Vulvar melanoma - A multivariable analysis of 644 patients. OBSTETRICS AND GYNECOLOGY, 110(2), 296-301.

Impact of the human papilloma vaccine on cervical cancer
Chan, J. K., & Berek, J. S. (2007). Impact of the human papilloma vaccine on cervical cancer. JOURNAL OF CLINICAL ONCOLOGY, 25(20), 2975-2982.

The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13,918 patients
Chan, J. K., Urban, R., Hu, J. M., Shin, J. Y., Husain, A., & Kapp, D. S. (2007). The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13,918 patients. BRITISH JOURNAL OF CANCER, 96(12), 1817-1822.

Lymphadenectomy in endometrioid uterine cancer staging - How many lymph nodes are enough? A study of 11,443 patients
Chan, J. K., Urban, R., Cheung, M. K., Shin, J. Y., Husain, A., & Osann, K. (2007). Lymphadenectomy in endometrioid uterine cancer staging - How many lymph nodes are enough? A study of 11,443 patients. CANCER, 109(12), 2454-2460.

Influence of the gynecologic oncologist on the survival of ovarian cancer patients
Chan, J. K., Kapp, D. S., Shin, J. Y., Husain, A., Teng, N. N., & O'Malley, C. (2007). Influence of the gynecologic oncologist on the survival of ovarian cancer patients. OBSTETRICS AND GYNECOLOGY, 109(6), 1342-1350.

Ovarian conservation at the time of hysterectomy for benign disease
Parker, W. H., Broder, M. S., Liu, Z., Shoupe, D., Farquhar, C., & Berek, J. S. (2007). Ovarian conservation at the time of hysterectomy for benign disease. CLINICAL OBSTETRICS AND GYNECOLOGY, 50(2), 354-361.

Elective oophorectomy for benign gynecological disorders
Shoupe, D., Parker, W. H., Broder, M. S., Liu, Z., Farquhar, C., & Berek, J. S. (2007). Elective oophorectomy for benign gynecological disorders. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 14(3), 580-585.

Prognostic factors for uterine cancer in reproductive-aged women
Lee, N. K., Cheung, M. K., Shin, J. Y., Husain, A., Teng, N. N., & Chan, J. K. (2007). Prognostic factors for uterine cancer in reproductive-aged women. OBSTETRICS AND GYNECOLOGY, 109(3), 655-662.

CA125: Megadaltons of novel opportunities
Dorigo, O., & Berek, J. S. (2007). CA125: Megadaltons of novel opportunities. GYNECOLOGIC ONCOLOGY, 104(3), 505-507.

Prognostic factors responsible for survival in sex cord stromal tumors of the ovary- An analysis of 376 women
Zhang, M., Cheung, M. K., Shin, J. Y., Kapp, D. S., Husain, A., & Chan, J. K. (2007). Prognostic factors responsible for survival in sex cord stromal tumors of the ovary- An analysis of 376 women. GYNECOLOGIC ONCOLOGY, 104(2), 396-400.

Association of lymphadenectomy and survival in stage I ovarian cancer patients
Chan, J. K., Munro, E. G., Cheung, M. K., Husain, A., Teng, N. N., & Osann, K. (2007). Association of lymphadenectomy and survival in stage I ovarian cancer patients. OBSTETRICS AND GYNECOLOGY, 109(1), 12-19.

The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma
Parthasarathy, A., Cheung, M. K., Osann, K., Husain, A., Teng, N. N., & Chan, J. K. (2006). The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. GYNECOLOGIC ONCOLOGY, 103(3), 1095-1099.

Ovarian cancer in younger vs older women: a population-based analysis
Chan, J. K., Urban, R., Cheung, M. K., Osann, K., Husain, A., & Leiserowitz, G. S. (2006). Ovarian cancer in younger vs older women: a population-based analysis. BRITISH JOURNAL OF CANCER, 95(10), 1314-1320.

Response to commentaries on retention of the ovaries and long-term survival after hysterectomy
Parker, W. H., Broder, M. S., Liu, Z., Shoupe, D., Farquhar, C., & Berek, J. S. (2006). Response to commentaries on retention of the ovaries and long-term survival after hysterectomy. CLIMACTERIC, 9(5), 396-398.

Patterns and progress in ovarian cancer over 14 years
Chan, J. K., Cheung, M. K., Husain, A., Teng, N. N., West, D., & Osann, K. (2006). Patterns and progress in ovarian cancer over 14 years. OBSTETRICS AND GYNECOLOGY, 108(3), 521-528.

Intraperitoneal chemotherapy for ovarian cancer
Hamilton, C. A., & Berek, J. S. (2006). Intraperitoneal chemotherapy for ovarian cancer. CURRENT OPINION IN ONCOLOGY, 18(5), 507-515.

Surgery for ovarian cancer: how to improve survival
Bristow, R. E., & Berek, J. S. (2006). Surgery for ovarian cancer: how to improve survival. LANCET, 367(9522), 1558-1560.

10th Biennial Helene Harris Memorial Trust Meeting
Balkwill, F. R., Ashworth, A., Bast, R. C., Berek, J. S., Boyd, J., & Urban, N. D. (2006). 10th Biennial Helene Harris Memorial Trust Meeting. CANCER RESEARCH, 66(6), 2904-2906.

Progress in ovarian cancer research: Proceedings of the 5th biennial ovarian cancer research symposium
Disis, M. L., Rivkin, S. E., Baron, A., Markman, M., Connolly, D., & Berek, J. S. (2006). Progress in ovarian cancer research: Proceedings of the 5th biennial ovarian cancer research symposium. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 16(2), 463-469.

An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer
Bryan, D. N., Radbod, R., & Berek, J. S. (2006). An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 16(1), 125-134.

Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLA
Berek, J. S., Howe, C., Lagasse, L. D., & Hacker, N. F. (2005). Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLA. GYNECOLOGIC ONCOLOGY, 99(1), 153-159.

Design, conduct and evaluation of a communication course for oncology fellows
Lenzi, R., Baile, W. F., Berek, J., Back, A., Buckman, R., & Parker, P. A. (2005). Design, conduct and evaluation of a communication course for oncology fellows. JOURNAL OF CANCER EDUCATION, 20(3), 143-149.

Lower urinary tract reconstruction with ileum in. the treatment of gynecologic malignancies
Elkas, J. C., Berek, J. S., Leuchter, R., Lagasse, L. D., & Karlan, B. Y. (2005). Lower urinary tract reconstruction with ileum in. the treatment of gynecologic malignancies. GYNECOLOGIC ONCOLOGY, 97(2), 685-692.

Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial
Monk, B. J., Wang, J. M., Im, S., Stock, R. J., Peters, W. A., & ALBERTS, D. S. (2005). Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. GYNECOLOGIC ONCOLOGY, 96(3), 721-728.

Monoclonal antibody therapy of ovarian cancer
Nicodemus, C. F., & Berek, J. S. (2005). Monoclonal antibody therapy of ovarian cancer. EXPERT REVIEW OF ANTICANCER THERAPY, 5(1), 87-96.

Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study
Muggia, F. M., Blessing, J. A., Waggoner, S., Berek, J. S., Monk, B. J., & Pearl, M. L. (2005). Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. GYNECOLOGIC ONCOLOGY, 96(1), 108-111.

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer
Berek, J. S., Taylor, P. T., Gordon, A., Cunningham, M. J., Finkler, N., & Nicodemus, C. F. (2004). Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY, 22(17), 3507-3516.

Using fresh tissue dissection to teach human anatomy in the clinical years
Robinson, A. G., Metten, S., Guiton, G., & Berek, J. (2004). Using fresh tissue dissection to teach human anatomy in the clinical years. ACADEMIC MEDICINE, 79(7), 711-716.

Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab
Berek, J. S. (2004). Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. EXPERT OPINION ON BIOLOGICAL THERAPY, 4(7), 1159-1165.

Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy
Nouriani, M., Bahador, A., Berek, J. S., Cheng, J. P., Chi, D. S., & Dubeau, L. (2004). Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. CLINICAL CANCER RESEARCH, 10(8), 2681-2686.

Lymphovascular and perineural invasion in the parametria: A prognostic factor for early-stage cervical cancer
Memarzadeh, S., Natarajan, S., Dandade, D. P., Ostrzega, N., Saber, P. A., & Berek, J. S. (2003). Lymphovascular and perineural invasion in the parametria: A prognostic factor for early-stage cervical cancer. OBSTETRICS AND GYNECOLOGY, 102(3), 612-619.

Current research and treatment for epithelial ovarian cancer - A Position Paper from the Helene Harris Memorial Trust
Balkwill, F., Bast, R. C., Berek, J., Chenevix-Trench, G., Gore, M., & Smyth, J. (2003). Current research and treatment for epithelial ovarian cancer - A Position Paper from the Helene Harris Memorial Trust. EUROPEAN JOURNAL OF CANCER, 39(13), 1818-1827.

Cervical cancer: An opportunity to prevent and cure
Berek, J. S. (2003). Cervical cancer: An opportunity to prevent and cure. CANCER JOURNAL, 9(5), 325-326.

Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies
Gold, M. A., Walker, J. L., Berek, J. S., Hallum, A. V., Garcia, D. J., & ALBERTS, D. S. (2003). Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies. GYNECOLOGIC ONCOLOGY, 90(2), 325-330.

Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
Fracasso, P. M., Blessing, J. A., Wolf, J., Rocereto, T. F., Berek, J. S., & Waggoner, S. (2003). Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY, 90(1), 177-180.

Progress in the management of gynecologic cancer: consensus summary statement.
Cannistra, S. A., Bast, R. C., Berek, J. S., Bookman, M. A., Crum, C. P., & King, L. (2003). Progress in the management of gynecologic cancer: consensus summary statement. Journal of clinical oncology , 21(10), 129s-132s.

Biologic and immunologic therapies for ovarian cancer.
Berek, J. S., Schultes, B. C., & Nicodemus, C. F. (2003). Biologic and immunologic therapies for ovarian cancer. Journal of clinical oncology , 21(10), 168s-174s.

Surgical resection of solitary brain metastasis from cervical cancer
Tajran, D., & Berek, J. S. (2003). Surgical resection of solitary brain metastasis from cervical cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 13(3), 368-370.

The use of continuous infusion topotecan in persistent and recurrent ovarian cancer
Elkas, J. C., Holschneider, C. H., Katz, B., Li, A. J., Louie, R., & Berek, J. S. (2003). The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 13(2), 138-141.

CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer
Memarzadeh, S., Lee, S. B., Berek, J. S., & Farias-Eisner, R. (2003). CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 13(2), 120-124.

Simplification of the new Bethesda 2001 classification System
Berek, J. S. (2003). Simplification of the new Bethesda 2001 classification System. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 188(3), S2-S5.

Specific keynote: Immunological therapy for ovarian cancer
Berek, J. S., Dorigo, O., Schultes, B., & Nicodemus, C. (2003). Specific keynote: Immunological therapy for ovarian cancer. GYNECOLOGIC ONCOLOGY, 88(1), S105-S109.

FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival
Memarzadeh, S., Holschneider, C. H., Bristow, R. E., JONES, N. L., Fu, Y. S., & Farias-Eisner, R. (2002). FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 12(5), 454-458.

Advances in the management of epithelial ovarian cancer
Memarzadeh, S., & Berek, J. S. (2001). Advances in the management of epithelial ovarian cancer. JOURNAL OF REPRODUCTIVE MEDICINE, 46(7), 621-629.

A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature
Ghosh, K., Dorigo, O., Bristow, R., & Berek, J. (2000). A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 191(2), 212-215.

Interferon plus chemotherapy for primary treatment of ovarian cancer
Berek, J. S. (2000). Interferon plus chemotherapy for primary treatment of ovarian cancer. LANCET, 356(9223), 6-7.

[Epithelial ovarian cancer (advanced stage): consensus conference (1998)].
Berek, J. S., Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., & Willemse, P. H. (2000). [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. Gynécologie, obstétrique & fertilité, 28(7-8), 576-583.

Ovarian cancer: Epidemiology, biology, and prognostic factors
Holschneider, C. H., & Berek, J. S. (2000). Ovarian cancer: Epidemiology, biology, and prognostic factors. SEMINARS IN SURGICAL ONCOLOGY, 19(1), 3-10.

Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125
Berek, J. S. (2000). Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125. GYNECOLOGIC ONCOLOGY, 77(2), 225-226.

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
Peters, W. A., Liu, P. Y., Barrett, R. J., Stock, R. J., Monk, B. J., & ALBERTS, D. S. (2000). Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. JOURNAL OF CLINICAL ONCOLOGY, 18(8), 1606-1613.

Fraud. What is the evidence?
Berek, J., Gutierrez, N., Stone, J., & Testa, L. (2000). Fraud. What is the evidence?. Care management journals : Journal of case management ; The journal of long term home health care, 2(1), 44-53.

IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile
Horton, H. M., Dorigo, O., Hernandez, P., Anderson, D., Berek, J. S., & Parker, S. E. (1999). IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. JOURNAL OF IMMUNOLOGY, 163(12), 6378-6385.

Endometrial cancer: Recent developments in evaluation and treatment
Chen, L. M., McGonigle, K. F., & Berek, J. S. (1999). Endometrial cancer: Recent developments in evaluation and treatment. ONCOLOGY-NEW YORK, 13(12), 1665-?.

Recurrent mature cystic teratoma presenting as a perihepatic mass
Chen, L. M., Nelson, S. D., & Berek, J. S. (1999). Recurrent mature cystic teratoma presenting as a perihepatic mass. OBSTETRICS AND GYNECOLOGY, 94(5), 856-856.

Intraperitoneal interferon-alpha in residual ovarian carcinoma: A Phase II Gynecologic Oncology Group study
Berek, J. S., Markman, M., Stonebraker, B., Lentz, S. S., Adelson, M. D., & Moore, D. (1999). Intraperitoneal interferon-alpha in residual ovarian carcinoma: A Phase II Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY, 75(1), 10-14.

Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study
Berek, J. S., Markman, M., Blessing, J. A., Kucera, P. R., Nelson, B. E., & Hanjani, P. (1999). Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY, 74(1), 48-52.

Advanced epithelial ovarian cancer: 1998 consensus statements
Berek, J. S., Bertelsen, K., du Bois, A., Brady, M. F., Carmichael, J., & Willemse, P. Hb. (1999). Advanced epithelial ovarian cancer: 1998 consensus statements. ANNALS OF ONCOLOGY, 10, 87-92.

Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future?
HAMILTON, T. C., Berek, J. S., & Kaye, S. B. (1999). Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future?. ANNALS OF ONCOLOGY, 10, 69-73.

Surgery during chemotherapy and at relapse of ovarian cancer
Berek, J. S., Trope, C., & Vergote, I. (1999). Surgery during chemotherapy and at relapse of ovarian cancer. ANNALS OF ONCOLOGY, 10, 3-7.

A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma. A gynecologic oncology group study
Feun, L. G., Blessing, J. A., Major, F. J., Disaia, P. J., Alvarez, R. D., & Berek, J. S. (1998). A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma. A gynecologic oncology group study. GYNECOLOGIC ONCOLOGY, 71(3), 410-415.

Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model
Dorigo, O., Shawler, D. L., Royston, I., SOBOL, R. E., Berek, J. S., & Fakhrai, H. (1998). Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. GYNECOLOGIC ONCOLOGY, 71(2), 204-210.

Psammocarcinoma with an aggressive course
Poggi, S. H., Bristow, R. E., Nieberg, R. K., & Berek, J. S. (1998). Psammocarcinoma with an aggressive course. OBSTETRICS AND GYNECOLOGY, 92(4), 659-661.

Reducing loss-to-follow-up among women with abnormal Pap smears - Results from a randomized trial testing an intensive follow-up protocol and economic incentives
Marcus, A. C., Kaplan, C. P., Crane, L. A., Berek, J. S., Bernstein, G., & McClatchey, M. W. (1998). Reducing loss-to-follow-up among women with abnormal Pap smears - Results from a randomized trial testing an intensive follow-up protocol and economic incentives. MEDICAL CARE, 36(3), 397-410.

Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer.
Kim, Y. B., Ghosh, K., Ainbinder, S., & Berek, J. S. (1998). Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer. Cancer treatment and research, 95, 253-276.

Progress in ovarian cancer
Chen, L., & Berek, J. S. (1998). Progress in ovarian cancer. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 10(1), 51-56.

Gene therapy for ovarian cancer: Development of novel treatment strategies
Dorigo, O., & Berek, J. S. (1997). Gene therapy for ovarian cancer: Development of novel treatment strategies. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 7(1), 1-13.

Dysgerminoma: The role of conservative surgery
Casey, A. C., Bhodauria, S., Shapter, A., NIEBERG, R., Barek, J. S., & FARIASEISNER, R. (1996). Dysgerminoma: The role of conservative surgery. GYNECOLOGIC ONCOLOGY, 63(3), 352-357.

Complete debulking of epithelial ovarian cancer.
Berek, J. S. (1996). Complete debulking of epithelial ovarian cancer. cancer journal from Scientific American, 2(3), 132-133.

Mixed mesodermal sarcoma of the ovary in a young patient
Fowler, J. M., Nathan, L., Nieberg, R. K., & Berek, J. S. (1996). Mixed mesodermal sarcoma of the ovary in a young patient. EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 65(2), 249-253.

Evidence for a unifocal origin in familial ovarian cancer
Gallion, H. H., Guarino, D., DePriest, P. D., VANNAGELL, J. R., Vaccarello, L., & Pieretti, M. (1996). Evidence for a unifocal origin in familial ovarian cancer. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 174(4), 1102-1106.

Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma
Kim, Y. B., Berek, J. S., MARTINEZMAZA, O., & Satyaswaroop, P. G. (1996). Vascular endothelial growth factor expression is not regulated by estradiol or medroxyprogesterone acetate in endometrial carcinoma. GYNECOLOGIC ONCOLOGY, 61(1), 97-100.

OVARIAN-CANCER SCREENING - THE USE OF SERIAL COMPLEMENTARY TUMOR-MARKERS TO IMPROVE SENSITIVITY AND SPECIFICITY FOR EARLY DETECTION
Berek, J. S., & Bast, R. C. (1995). OVARIAN-CANCER SCREENING - THE USE OF SERIAL COMPLEMENTARY TUMOR-MARKERS TO IMPROVE SENSITIVITY AND SPECIFICITY FOR EARLY DETECTION. CANCER, 76(10), 2092-2096.

RADIATION-THERAPY FOR ADENOCARCINOMA OF THE UTERINE CERVIX - DOES THE HISTOLOGY MATTER
Berek, J. S. (1995). RADIATION-THERAPY FOR ADENOCARCINOMA OF THE UTERINE CERVIX - DOES THE HISTOLOGY MATTER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 32(5), 1543-1544.

OVARIAN-CANCER SPREAD - IS LAPAROSCOPY TO BLAME
Berek, J. S. (1995). OVARIAN-CANCER SPREAD - IS LAPAROSCOPY TO BLAME. LANCET, 346(8969), 200-200.

ASSESSMENT OF DOSE-INTENSIVE THERAPY IN SUBOPTIMALLY DEBULKED OVARIAN-CANCER - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
McGuire, W. P., Hoskins, W. J., Brady, M. F., Homesley, H. D., Creasman, W. T., & Woodward, J. (1995). ASSESSMENT OF DOSE-INTENSIVE THERAPY IN SUBOPTIMALLY DEBULKED OVARIAN-CANCER - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY. JOURNAL OF CLINICAL ONCOLOGY, 13(7), 1589-1599.

INTERVAL DEBULKING OF OVARIAN-CANCER - AN INTERIM MEASURE
Berek, J. S. (1995). INTERVAL DEBULKING OF OVARIAN-CANCER - AN INTERIM MEASURE. NEW ENGLAND JOURNAL OF MEDICINE, 332(10), 675-677.

INTRAPERITONEAL ADMINISTRATION OF CISPLATIN AND 5-FLUOROURACIL IN RESIDUAL OVARIAN-CANCER - A PHASE-II GYNECOLOGIC-ONCOLOGY-GROUP TRIAL
Braly, P. S., Berek, J. S., Blessing, J. A., Homesley, H. D., & Averette, H. (1995). INTRAPERITONEAL ADMINISTRATION OF CISPLATIN AND 5-FLUOROURACIL IN RESIDUAL OVARIAN-CANCER - A PHASE-II GYNECOLOGIC-ONCOLOGY-GROUP TRIAL. GYNECOLOGIC ONCOLOGY, 56(2), 164-168.

Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer, May 4-7, 1995, Glasgow, UK.
Sharp, F., Blackett, A. D., Leake, R. E., & Berek, J. S. (1995). Conclusions and recommendations from the Helene Harris Memorial Trust Fifth Biennial International Forum on Ovarian Cancer, May 4-7, 1995, Glasgow, UK. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 5(6), 449-458.

A MULTICENTER STUDY OF LAPAROSCOPIC MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN
Parker, W. H., Levine, R. L., Howard, F. M., SANSONE, B., & Berek, J. S. (1994). A MULTICENTER STUDY OF LAPAROSCOPIC MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 179(6), 733-737.

PROGNOSTIC IMPORTANCE OF INTRAOPERATIVE RUPTURE OF MALIGNANT OVARIAN EPITHELIAL NEOPLASMS
Parker, W. H., & Berek, J. S. (1994). PROGNOSTIC IMPORTANCE OF INTRAOPERATIVE RUPTURE OF MALIGNANT OVARIAN EPITHELIAL NEOPLASMS. OBSTETRICS AND GYNECOLOGY, 84(5), 897-897.

THE INFLUENCE OF TUMOR GRADE, DISTRIBUTION, AND EXTENT OF CARCINOMATOSIS IN MINIMAL RESIDUAL STAGE-III EPITHELIAL OVARIAN-CANCER AFTER OPTIMAL PRIMARY CYTOREDUCTIVE SURGERY
FARIASEISNER, R., Teng, F., Oliveira, M., Leuchter, R., Karlan, B., & Berek, J. S. (1994). THE INFLUENCE OF TUMOR GRADE, DISTRIBUTION, AND EXTENT OF CARCINOMATOSIS IN MINIMAL RESIDUAL STAGE-III EPITHELIAL OVARIAN-CANCER AFTER OPTIMAL PRIMARY CYTOREDUCTIVE SURGERY. GYNECOLOGIC ONCOLOGY, 55(1), 108-110.

Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes.
Casey, A. C., & Berek, J. S. (1994). Papillary serous cystadenocarcinoma arising in benign glandular inclusion cysts in pelvic and inguinal lymph nodes. Obstetrics and gynecology, 84(4), 724-726.

Advances in the biology of gynecologic cancer.
Gotlieb, W. H., & Berek, J. S. (1994). Advances in the biology of gynecologic cancer. Current opinion in oncology, 6(5), 513-518.

SALVAGE THERAPY FOR RECURRENT AND REFRACTORY OVARIAN-CANCER WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY
Broun, E. R., Belinson, J. L., Berek, J. S., McIntosh, D., Hurd, D., & Williams, S. (1994). SALVAGE THERAPY FOR RECURRENT AND REFRACTORY OVARIAN-CANCER WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW SUPPORT - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY. GYNECOLOGIC ONCOLOGY, 54(2), 142-146.

SURGICAL-MANAGEMENT OF OVARIAN-CANCER
FARIASEISNER, R., Kim, Y. B., & Berek, J. S. (1994). SURGICAL-MANAGEMENT OF OVARIAN-CANCER. SEMINARS IN SURGICAL ONCOLOGY, 10(4), 268-275.

MOLECULAR AND BIOLOGIC FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER
Berek, J. S., & MARTINEZMAZA, T. (1994). MOLECULAR AND BIOLOGIC FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER. JOURNAL OF REPRODUCTIVE MEDICINE, 39(4), 241-248.

CYTOKINE-INDUCED MODULATION OF TUMOR-SUPPRESSOR GENE-EXPRESSION IN OVARIAN-CANCER CELLS - UP-REGULATION OF P53 GENE-EXPRESSION AND INDUCTION OF APOPTOSIS BY TUMOR-NECROSIS-FACTOR-ALPHA
Gotlieb, W. H., Watson, J. M., Rezai, A., Johnson, M., MARTINEZMAZA, O., & Berek, J. S. (1994). CYTOKINE-INDUCED MODULATION OF TUMOR-SUPPRESSOR GENE-EXPRESSION IN OVARIAN-CANCER CELLS - UP-REGULATION OF P53 GENE-EXPRESSION AND INDUCTION OF APOPTOSIS BY TUMOR-NECROSIS-FACTOR-ALPHA. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 170(4), 1121-1130.

CONSERVATIVE AND INDIVIDUALIZED SURGERY FOR EARLY SQUAMOUS CARCINOMA OF THE VULVA - THE TREATMENT OF CHOICE FOR STAGE-I AND II (T1-2N0-1M0) DISEASE
FARIASEISNER, R., Cirisano, F. D., GROUSE, D., Leuchter, R. S., Karlan, B. Y., & Berek, J. S. (1994). CONSERVATIVE AND INDIVIDUALIZED SURGERY FOR EARLY SQUAMOUS CARCINOMA OF THE VULVA - THE TREATMENT OF CHOICE FOR STAGE-I AND II (T1-2N0-1M0) DISEASE. GYNECOLOGIC ONCOLOGY, 53(1), 55-58.

THE EFFECT OF DIAMETER OF LARGEST RESIDUAL DISEASE ON SURVIVAL AFTER PRIMARY CYTOREDUCTIVE SURGERY IN PATIENTS WITH SUBOPTIMAL RESIDUAL EPITHELIAL OVARIAN-CARCINOMA
Hoskins, W. J., McGuire, W. P., Brady, M. F., Homesley, H. D., Creasman, W. T., & Berek, J. S. (1994). THE EFFECT OF DIAMETER OF LARGEST RESIDUAL DISEASE ON SURVIVAL AFTER PRIMARY CYTOREDUCTIVE SURGERY IN PATIENTS WITH SUBOPTIMAL RESIDUAL EPITHELIAL OVARIAN-CARCINOMA. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 170(4), 974-980.

LAPAROSCOPIC MANAGEMENT OF THE ADNEXAL MASS
Parker, W. H., & Berek, J. S. (1994). LAPAROSCOPIC MANAGEMENT OF THE ADNEXAL MASS. OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 21(1), 79-92.

UTERINE SARCOMA IN PATIENTS OPERATED ON FOR PRESUMED LEIOMYOMA AND RAPIDLY GROWING LEIOMYOMA
Parker, W. H., Fu, Y. S., & Berek, J. S. (1994). UTERINE SARCOMA IN PATIENTS OPERATED ON FOR PRESUMED LEIOMYOMA AND RAPIDLY GROWING LEIOMYOMA. OBSTETRICS AND GYNECOLOGY, 83(3), 414-418.

Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal carcinomatosis.
Fowler, J. M., Nieberg, R. K., Schooler, T. A., & Berek, J. S. (1994). Peritoneal adenocarcinoma (serous) of Müllerian type: a subgroup of women presenting with peritoneal carcinomatosis. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 4(1), 43-51.

Management of Selected Adnexal Masses in Postmenopausal Women by Operative Laparoscopy-A Multicentered Study
Parker, W. H., Levine, R. L., Howard, F. M., Sansone, B., & Berek, J. S. (1994). Management of Selected Adnexal Masses in Postmenopausal Women by Operative Laparoscopy-A Multicentered Study. The Journal of the American Association of Gynecologic Laparoscopists, 1(4, Part 2), S27.

Fine-needle aspiration cytology in the management of gynecologic oncology patients.
Layfield, L. J., & Berek, J. S. (1994). Fine-needle aspiration cytology in the management of gynecologic oncology patients. Cancer treatment and research, 70, 1-13.

CONSTITUTIVE PRODUCTION OF MACROPHAGE-COLONY-STIMULATING FACTOR AND INTERLEUKIN-6 BY HUMAN OVARIAN SURFACE EPITHELIAL-CELLS
LIDOR, Y. J., Xu, F. J., MARTINEZMAZA, O., Olt, G. J., Marks, J. R., & Bast, R. C. (1993). CONSTITUTIVE PRODUCTION OF MACROPHAGE-COLONY-STIMULATING FACTOR AND INTERLEUKIN-6 BY HUMAN OVARIAN SURFACE EPITHELIAL-CELLS. EXPERIMENTAL CELL RESEARCH, 207(2), 332-339.

PROGNOSTIC FACTORS FOR GROIN NODE METASTASIS IN SQUAMOUS-CELL CARCINOMA OF THE VULVA (A GYNECOLOGIC-ONCOLOGY-GROUP-STUDY)
Homesley, H. D., Bundy, B. N., Sedlis, A., YORDAN, E., Berek, J. S., & MORTEL, R. (1993). PROGNOSTIC FACTORS FOR GROIN NODE METASTASIS IN SQUAMOUS-CELL CARCINOMA OF THE VULVA (A GYNECOLOGIC-ONCOLOGY-GROUP-STUDY). GYNECOLOGIC ONCOLOGY, 49(3), 279-283.

IMPACT OF CONTRACEPTION ON GYNECOLOGIC CANCERS
Herbst, A. L., & Berek, J. S. (1993). IMPACT OF CONTRACEPTION ON GYNECOLOGIC CANCERS. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 168(6), 1980-1985.

GROWTH-INHIBITION OF OVARIAN-CANCER CELLS INDUCED BY ANTISENSE IL-6 OLIGONUCLEOTIDES
Watson, J. M., Berek, J. S., & MARTINEZMAZA, O. (1993). GROWTH-INHIBITION OF OVARIAN-CANCER CELLS INDUCED BY ANTISENSE IL-6 OLIGONUCLEOTIDES. GYNECOLOGIC ONCOLOGY, 49(1), 8-15.

SOLITARY RECURRENT METASTASIS OF EPITHELIAL OVARIAN-CANCER IN THE SPLEEN
FARIASEISNER, R., Braly, P., & Berek, J. S. (1993). SOLITARY RECURRENT METASTASIS OF EPITHELIAL OVARIAN-CANCER IN THE SPLEEN. GYNECOLOGIC ONCOLOGY, 48(3), 338-341.

PRIMARY LEIOMYOSARCOMA OF THE OVARY IN A PERIMENARCHAL FEMALE
Monk, B. J., NIEBERG, R., & Berek, J. S. (1993). PRIMARY LEIOMYOSARCOMA OF THE OVARY IN A PERIMENARCHAL FEMALE. GYNECOLOGIC ONCOLOGY, 48(3), 389-393.

SENSITIVITY OF DRUG-RESISTANT HUMAN OVARIAN TUMOR-CELL LINES TO COMBINED EFFECTS OF TUMOR-NECROSIS-FACTOR (TNF-ALPHA) AND DOXORUBICIN - FAILURE OF THE COMBINATION TO MODULATE THE MDR PHENOTYPE
Safrit, J. T., Berek, J. S., & Bonavida, B. (1993). SENSITIVITY OF DRUG-RESISTANT HUMAN OVARIAN TUMOR-CELL LINES TO COMBINED EFFECTS OF TUMOR-NECROSIS-FACTOR (TNF-ALPHA) AND DOXORUBICIN - FAILURE OF THE COMBINATION TO MODULATE THE MDR PHENOTYPE. GYNECOLOGIC ONCOLOGY, 48(2), 214-220.

Current management of invasive squamous carcinoma of the vulva.
Farias-Eisner, R., & Berek, J. S. (1993). Current management of invasive squamous carcinoma of the vulva. Clinics in geriatric medicine, 9(1), 131-143.

MOLECULAR AND BIOLOGICAL FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER
Berek, J. S., MARTINEZMAZA, O., Hamilton, T., Trope, C., Kaern, J., & Rustin, G. Js. (1993). MOLECULAR AND BIOLOGICAL FACTORS IN THE PATHOGENESIS OF OVARIAN-CANCER. ANNALS OF ONCOLOGY, 4, 3-16.

ADVANCED EPITHELIAL OVARIAN-CANCER - 1993 CONSENSUS STATEMENTS
Allen, D. G., Baak, J., Belpomme, D., Berek, J. S., Bertelsen, K., & DeVries, E. Ge. (1993). ADVANCED EPITHELIAL OVARIAN-CANCER - 1993 CONSENSUS STATEMENTS. ANNALS OF ONCOLOGY, 4, 83-88.

Advanced ovarian cancer. Tumour markers.
Rustin, G. J., Van der Burg, M. E., & Berek, J. S. (1993). Advanced ovarian cancer. Tumour markers. Annals of oncology , 4, 71-77.

PRESENCE OF INTERLEUKIN 10 (IL-10) IN THE ASCITES OF PATIENTS WITH OVARIAN AND OTHER INTRAABDOMINAL CANCERS
Gotlieb, W. H., Abrams, J. S., Watson, J. M., VELU, T. J., Berek, J. S., & MARTINEZMAZA, O. (1992). PRESENCE OF INTERLEUKIN 10 (IL-10) IN THE ASCITES OF PATIENTS WITH OVARIAN AND OTHER INTRAABDOMINAL CANCERS. CYTOKINE, 4(5), 385-390.

BIOLOGIC AND IMMUNOLOGICAL THERAPY OF OVARIAN-CANCER
Bookman, M. A., & Berek, J. S. (1992). BIOLOGIC AND IMMUNOLOGICAL THERAPY OF OVARIAN-CANCER. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 6(4), 941-965.

INTRAPERITONEAL IMMUNOTHERAPY FOR OVARIAN-CANCER WITH ALPHA-INTERFERON
Berek, J. S. (1992). INTRAPERITONEAL IMMUNOTHERAPY FOR OVARIAN-CANCER WITH ALPHA-INTERFERON. EUROPEAN JOURNAL OF CANCER, 28A(4-5), 719-721.

CHARACTERISTICS OF PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER UNRESPONSIVE TO CISPLATIN-BASED IP CHEMOTHERAPY - LESSONS LEARNED FROM A GYNECOLOGIC ONCOLOGY GROUP PHASE-II TRIAL OF IP CISPLATIN AND RECOMBINANT ALPHA-INTERFERON
Markman, M., Berek, J. S., Blessing, J. A., McGuire, W. P., Bell, J., & Homesley, H. D. (1992). CHARACTERISTICS OF PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER UNRESPONSIVE TO CISPLATIN-BASED IP CHEMOTHERAPY - LESSONS LEARNED FROM A GYNECOLOGIC ONCOLOGY GROUP PHASE-II TRIAL OF IP CISPLATIN AND RECOMBINANT ALPHA-INTERFERON. GYNECOLOGIC ONCOLOGY, 45(1), 3-8.

IMPROVING ADHERENCE TO SCREENING FOLLOW-UP AMONG WOMEN WITH ABNORMAL PAP SMEARS - RESULTS FROM A LARGE CLINIC-BASED TRIAL OF 3 INTERVENTION STRATEGIES
Marcus, A. C., Crane, L. A., Kaplan, C. P., READING, A. E., Savage, E., & Berek, J. S. (1992). IMPROVING ADHERENCE TO SCREENING FOLLOW-UP AMONG WOMEN WITH ABNORMAL PAP SMEARS - RESULTS FROM A LARGE CLINIC-BASED TRIAL OF 3 INTERVENTION STRATEGIES. MEDICAL CARE, 30(3), 216-230.

STIMULATION OF OVARIAN TUMOR-CELL PROLIFERATION WITH MONOCYTE PRODUCTS INCLUDING INTERLEUKIN-1, INTERLEUKIN-6, AND TUMOR-NECROSIS-FACTOR-ALPHA
Wu, S., Rodabaugh, K., MARTINEZMAZA, O., Watson, J. M., Silberstein, D. S., & Bast, R. C. (1992). STIMULATION OF OVARIAN TUMOR-CELL PROLIFERATION WITH MONOCYTE PRODUCTS INCLUDING INTERLEUKIN-1, INTERLEUKIN-6, AND TUMOR-NECROSIS-FACTOR-ALPHA. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 166(3), 997-1007.

EARLY-STAGE SQUAMOUS-CELL AND ADENOCARCINOMA OF THE CERVIX
McGonigle, K. F., & Berek, J. S. (1992). EARLY-STAGE SQUAMOUS-CELL AND ADENOCARCINOMA OF THE CERVIX. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 4(1), 109-119.

2ND-LOOK VERSUS 2ND NATURE
Berek, J. S. (1992). 2ND-LOOK VERSUS 2ND NATURE. GYNECOLOGIC ONCOLOGY, 44(1), 1-2.

Interleukin 6 and cancer treatment.
Martínez-Maza, O., & Berek, J. S. (1991). Interleukin 6 and cancer treatment. In vivo , 5(6), 583-588.

CONCURRENT CISPLATIN AND 5-FLUOROURACIL CHEMOTHERAPY AND RADIATION-THERAPY FOR ADVANCED-STAGE SQUAMOUS CARCINOMA OF THE VULVA
Berek, J. S., HEAPS, J. M., Fu, Y. S., Juillard, G. Jf., & Hacker, N. F. (1991). CONCURRENT CISPLATIN AND 5-FLUOROURACIL CHEMOTHERAPY AND RADIATION-THERAPY FOR ADVANCED-STAGE SQUAMOUS CARCINOMA OF THE VULVA. GYNECOLOGIC ONCOLOGY, 42(3), 197-201.

ADNEXAL TORSION - AN UNUSUAL CAUSE OF ABDOMINAL-PAIN IN POSTMENOPAUSAL WOMEN
Shih, S., Vetto, J. T., Berek, J. S., HEAPS, J. M., & Hiatt, J. R. (1991). ADNEXAL TORSION - AN UNUSUAL CAUSE OF ABDOMINAL-PAIN IN POSTMENOPAUSAL WOMEN. AMERICAN SURGEON, 57(5), 327-329.

ASSESSMENT OF CURRENT INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING OF VULVAR CARCINOMA RELATIVE TO PROGNOSTIC FACTORS FOR SURVIVAL (A GYNECOLOGIC ONCOLOGY GROUP-STUDY)
Homesley, H. D., Bundy, B. N., Sedlis, A., YORDAN, E., Berek, J. S., & MORTEL, R. (1991). ASSESSMENT OF CURRENT INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING OF VULVAR CARCINOMA RELATIVE TO PROGNOSTIC FACTORS FOR SURVIVAL (A GYNECOLOGIC ONCOLOGY GROUP-STUDY). AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 164(4), 997-1004.

SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER
Berek, J. S., Chung, C., Kaldi, K., Watson, J. M., Knox, R. M., & MARTINEZMAZA, O. (1991). SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 164(4), 1038-1043.

A PHASE I-II TRIAL OF INTRAPERITONEAL CISPLATIN AND ALPHA-INTERFERON IN PATIENTS WITH PERSISTENT EPITHELIAL OVARIAN-CANCER
Berek, J. S., WELANDER, C., Schink, J. C., Grossberg, H., Montz, F. J., & ZIGELBOIM, J. (1991). A PHASE I-II TRIAL OF INTRAPERITONEAL CISPLATIN AND ALPHA-INTERFERON IN PATIENTS WITH PERSISTENT EPITHELIAL OVARIAN-CANCER. GYNECOLOGIC ONCOLOGY, 40(3), 237-243.

FINE-NEEDLE ASPIRATION CYTOLOGY ACCURACY WITH PALPABLE GYNECOLOGIC NEOPLASMS
Layfield, L. J., HEAPS, J. M., & Berek, J. S. (1991). FINE-NEEDLE ASPIRATION CYTOLOGY ACCURACY WITH PALPABLE GYNECOLOGIC NEOPLASMS. GYNECOLOGIC ONCOLOGY, 40(1), 70-73.

SURGICAL STAGING OF CERVICAL-CANCER
HEAPS, J. M., & Berek, J. S. (1990). SURGICAL STAGING OF CERVICAL-CANCER. CLINICAL OBSTETRICS AND GYNECOLOGY, 33(4), 852-863.

RESISTANCE OF HUMAN OVARIAN-CANCER CELLS TO TUMOR-NECROSIS-FACTOR AND LYMPHOKINE-ACTIVATED KILLER-CELLS - CORRELATION WITH EXPRESSION OF HER2 NEU ONCOGENES
Lichtenstein, A., Berenson, J., Gera, J. F., Waldburger, K., MARTINEZMAZA, O., & Berek, J. S. (1990). RESISTANCE OF HUMAN OVARIAN-CANCER CELLS TO TUMOR-NECROSIS-FACTOR AND LYMPHOKINE-ACTIVATED KILLER-CELLS - CORRELATION WITH EXPRESSION OF HER2 NEU ONCOGENES. CANCER RESEARCH, 50(22), 7364-7370.

MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN BY OPERATIVE LAPAROSCOPY - A PILOT-STUDY
Parker, W. H., & Berek, J. S. (1990). MANAGEMENT OF SELECTED CYSTIC ADNEXAL MASSES IN POSTMENOPAUSAL WOMEN BY OPERATIVE LAPAROSCOPY - A PILOT-STUDY. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 163(5), 1574-1577.

CONSTITUTIVE PRODUCTION OF INTERLEUKIN-6 BY OVARIAN-CANCER CELL-LINES AND BY PRIMARY OVARIAN TUMOR CULTURES
Watson, J. M., Sensintaffar, J. L., Berek, J. S., & MARTINEZMAZA, O. (1990). CONSTITUTIVE PRODUCTION OF INTERLEUKIN-6 BY OVARIAN-CANCER CELL-LINES AND BY PRIMARY OVARIAN TUMOR CULTURES. CANCER RESEARCH, 50(21), 6959-6965.

INTRAPERITONEAL ADOPTIVE IMMUNOTHERAPY FOR PERITONEAL CANCER
Berek, J. S. (1990). INTRAPERITONEAL ADOPTIVE IMMUNOTHERAPY FOR PERITONEAL CANCER. JOURNAL OF CLINICAL ONCOLOGY, 8(10), 1610-1612.

OVARIAN METASTASES ARE RARE IN STAGE-I ADENOCARCINOMA OF THE CERVIX
Brown, J. V., Fu, Y. S., & Berek, J. S. (1990). OVARIAN METASTASES ARE RARE IN STAGE-I ADENOCARCINOMA OF THE CERVIX. OBSTETRICS AND GYNECOLOGY, 76(4), 623-623.

SYNERGY IS DOCUMENTED INVITRO WITH LOW-DOSE RECOMBINANT TUMOR-NECROSIS-FACTOR, CISPLATIN, AND DOXORUBICIN IN OVARIAN-CANCER CELLS
Bonavida, B., Tsuchitani, T., ZIGHELBOIM, J., & Berek, J. S. (1990). SYNERGY IS DOCUMENTED INVITRO WITH LOW-DOSE RECOMBINANT TUMOR-NECROSIS-FACTOR, CISPLATIN, AND DOXORUBICIN IN OVARIAN-CANCER CELLS. GYNECOLOGIC ONCOLOGY, 38(3), 333-339.

SURGICAL-PATHOLOGICAL VARIABLES PREDICTIVE OF LOCAL RECURRENCE IN SQUAMOUS-CELL CARCINOMA OF THE VULVA
HEAPS, J. M., Fu, Y. S., Montz, F. J., Hacker, N. F., & Berek, J. S. (1990). SURGICAL-PATHOLOGICAL VARIABLES PREDICTIVE OF LOCAL RECURRENCE IN SQUAMOUS-CELL CARCINOMA OF THE VULVA. GYNECOLOGIC ONCOLOGY, 38(3), 309-314.

PATHOPHYSIOLOGY AND MANAGEMENT OF ENDOMETRIAL HYPERPLASIA AND CARCINOMA
Fu, Y. S., Gambone, J. C., Do, & Berek, J. S. (1990). PATHOPHYSIOLOGY AND MANAGEMENT OF ENDOMETRIAL HYPERPLASIA AND CARCINOMA. WESTERN JOURNAL OF MEDICINE, 153(1), 50-61.

MALIGNANT NEOPLASMS ARISING IN ENDOMETRIOSIS
HEAPS, J. M., Nieberg, R. K., & Berek, J. S. (1990). MALIGNANT NEOPLASMS ARISING IN ENDOMETRIOSIS. OBSTETRICS AND GYNECOLOGY, 75(6), 1023-1028.

CYTOREDUCTIVE SURGERY FOR ADVANCED OVARIAN-CANCER - CARDIOVASCULAR EVALUATION WITH PULMONARY-ARTERY CATHETERS
EISNER, R. F., Montz, F. J., & Berek, J. S. (1990). CYTOREDUCTIVE SURGERY FOR ADVANCED OVARIAN-CANCER - CARDIOVASCULAR EVALUATION WITH PULMONARY-ARTERY CATHETERS. GYNECOLOGIC ONCOLOGY, 37(3), 311-314.

PHASE-II STUDY OF N-METHYLFORMAMIDE (N-MF) (NSC 3051) IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
McGuire, W. P., Blessing, J. A., Berek, J. S., & Munoz, A. (1990). PHASE-II STUDY OF N-METHYLFORMAMIDE (N-MF) (NSC 3051) IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. INVESTIGATIONAL NEW DRUGS, 8(2), 191-194.

ADJUVANT THERAPY FOR EARLY-STAGE OVARIAN-CANCER
Berek, J. S. (1990). ADJUVANT THERAPY FOR EARLY-STAGE OVARIAN-CANCER. NEW ENGLAND JOURNAL OF MEDICINE, 322(15), 1076-1078.

RISK-FACTORS FOR THE DEVELOPMENT OF LYMPH-NODE METASTASIS IN VULVAR SQUAMOUS-CELL CARCINOMA
Binder, S. W., Huang, I., Fu, Y. S., Hacker, N. F., & Berek, J. S. (1990). RISK-FACTORS FOR THE DEVELOPMENT OF LYMPH-NODE METASTASIS IN VULVAR SQUAMOUS-CELL CARCINOMA. GYNECOLOGIC ONCOLOGY, 37(1), 9-16.

AUGMENTATION OF CYTOTOXICITY OF LYMPHOKINE ACTIVATED KILLER-CELLS ON OVARIAN TUMOR-CELLS BY VARIOUS BIOLOGICAL RESPONSE MODIFIERS
Nio, Y., ZIGHELBOIM, J., Berek, J. S., & Bonavida, B. (1990). AUGMENTATION OF CYTOTOXICITY OF LYMPHOKINE ACTIVATED KILLER-CELLS ON OVARIAN TUMOR-CELLS BY VARIOUS BIOLOGICAL RESPONSE MODIFIERS. ANTICANCER RESEARCH, 10(2A), 441-446.

PELVIC HEMANGIOPERICYTOMAS - A REPORT OF 5 CASES AND LITERATURE-REVIEW
Munoz, A. K., Berek, J. S., Fu, Y. S., & HEINTZ, P. Am. (1990). PELVIC HEMANGIOPERICYTOMAS - A REPORT OF 5 CASES AND LITERATURE-REVIEW. GYNECOLOGIC ONCOLOGY, 36(3), 380-382.

CYCLOHEXIMIDE-INDUCED MODULATION OF TNF-MEDIATED CYTOTOXICITY IN SENSITIVE AND RESISTANT OVARIAN TUMOR-CELLS
Nio, Y., ZIGHELBOIM, J., Berek, J., & Bonavida, B. (1990). CYCLOHEXIMIDE-INDUCED MODULATION OF TNF-MEDIATED CYTOTOXICITY IN SENSITIVE AND RESISTANT OVARIAN TUMOR-CELLS. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 26(1), 1-8.

RESECTION OF DIAPHRAGMATIC PERITONEUM AND MUSCLE - ROLE IN CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER
Montz, F. J., Schlaerth, J. B., & Berek, J. S. (1989). RESECTION OF DIAPHRAGMATIC PERITONEUM AND MUSCLE - ROLE IN CYTOREDUCTIVE SURGERY FOR OVARIAN-CANCER. GYNECOLOGIC ONCOLOGY, 35(3), 338-340.

Screening, diagnosis, and monitoring of gynecologic malignancies.
Montz, F. J., & Berek, J. S. (1989). Screening, diagnosis, and monitoring of gynecologic malignancies. Current opinion in oncology, 1(1), 75-81.

SYNERGISTIC EFFECT OF COMBINED INTRAPERITONEAL CISPLATIN AND CYTOSINE-ARABINOSIDE IN A MURINE OVARIAN-CANCER MODEL
Berek, J. S., Schink, J. C., & Knox, R. M. (1989). SYNERGISTIC EFFECT OF COMBINED INTRAPERITONEAL CISPLATIN AND CYTOSINE-ARABINOSIDE IN A MURINE OVARIAN-CANCER MODEL. OBSTETRICS AND GYNECOLOGY, 74(4), 663-666.

HUMAN NEUTROPHIL-MEDIATED LYSIS OF OVARIAN-CANCER CELLS
Lichtenstein, A., Seelig, M., Berek, J., & ZIGHELBOIM, J. (1989). HUMAN NEUTROPHIL-MEDIATED LYSIS OF OVARIAN-CANCER CELLS. BLOOD, 74(2), 805-809.

CYTO-TOXIC AND CYTOSTATIC EFFECTS OF THE STREPTOCOCCAL PREPARATION OK-432 AND ITS SUBCELLULAR-FRACTIONS ON HUMAN OVARIAN TUMOR-CELLS
Nio, Y., ZIGHELBOIM, J., Berek, J., & Bonavida, B. (1989). CYTO-TOXIC AND CYTOSTATIC EFFECTS OF THE STREPTOCOCCAL PREPARATION OK-432 AND ITS SUBCELLULAR-FRACTIONS ON HUMAN OVARIAN TUMOR-CELLS. CANCER, 64(2), 434-441.

UTILIZATION OF A MURINE MODEL TO OPTIMIZE VOLUME AND DWELL TIME OF INTRAPERITONEAL CISPLATIN
Pretorius, R. G., Eisenkop, S., Berek, J. S., Hacker, N. F., Ashikaga, T., & Lagasse, L. D. (1989). UTILIZATION OF A MURINE MODEL TO OPTIMIZE VOLUME AND DWELL TIME OF INTRAPERITONEAL CISPLATIN. GYNECOLOGIC ONCOLOGY, 34(1), 66-69.

SYNCHRONOUS PRIMARY NEOPLASMS OF THE FEMALE REPRODUCTIVE-TRACT
EISNER, R. F., Nieberg, R. K., & Berek, J. S. (1989). SYNCHRONOUS PRIMARY NEOPLASMS OF THE FEMALE REPRODUCTIVE-TRACT. GYNECOLOGIC ONCOLOGY, 33(3), 335-339.

LYMPHOCYTE-ACTIVATION BY RECOMBINANT INTERLEUKIN-2 IN OVARIAN-CANCER PATIENTS
Boyer, P. J., Berek, J. S., & ZIGHELBOIM, J. (1989). LYMPHOCYTE-ACTIVATION BY RECOMBINANT INTERLEUKIN-2 IN OVARIAN-CANCER PATIENTS. OBSTETRICS AND GYNECOLOGY, 73(5), 793-797.

VULVOVAGINAL MELANOMA - REPORT OF 7 CASES AND LITERATURE-REVIEW
Brand, E., Fu, Y. S., Lagasse, L. D., & Berek, J. S. (1989). VULVOVAGINAL MELANOMA - REPORT OF 7 CASES AND LITERATURE-REVIEW. GYNECOLOGIC ONCOLOGY, 33(1), 54-60.

RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE PLUS CISPLATIN WITH OR WITHOUT DOXORUBICIN IN OVARIAN-CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
Omura, G. A., Bundy, B. N., Berek, J. S., Curry, S., Delgado, G., & MORTEL, R. (1989). RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE PLUS CISPLATIN WITH OR WITHOUT DOXORUBICIN IN OVARIAN-CARCINOMA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. JOURNAL OF CLINICAL ONCOLOGY, 7(4), 457-465.

PERITONEAL CYTOLOGY OF OVARIAN-CANCER PATIENTS RECEIVING INTRAPERITONEAL THERAPY - QUANTITATION OF MALIGNANT-CELLS AND RESPONSE
Sagae, S., Berek, J. S., Fu, Y. S., Chang, N., Dauplat, J., & Hacker, N. F. (1988). PERITONEAL CYTOLOGY OF OVARIAN-CANCER PATIENTS RECEIVING INTRAPERITONEAL THERAPY - QUANTITATION OF MALIGNANT-CELLS AND RESPONSE. OBSTETRICS AND GYNECOLOGY, 72(5), 782-788.

INTRAPERITONEAL ADMINISTRATION OF HUMAN RECOMBINANT INTERFERON-ALPHA IN PATIENTS WITH OVARIAN-CANCER - EFFECTS ON LYMPHOCYTE PHENOTYPE AND CYTO-TOXICITY
Lichtenstein, A., Spina, C., Berek, J. S., Jung, T., & ZIGHELBOIM, J. (1988). INTRAPERITONEAL ADMINISTRATION OF HUMAN RECOMBINANT INTERFERON-ALPHA IN PATIENTS WITH OVARIAN-CANCER - EFFECTS ON LYMPHOCYTE PHENOTYPE AND CYTO-TOXICITY. CANCER RESEARCH, 48(20), 5853-5859.

SENSITIVITY OF FRESH AND CULTURED OVARIAN TUMOR-CELLS TO TUMOR NECROSIS FACTOR, INTERFERON-ALPHA-2, AND OK-432
Nio, Y., ZIGHELBOIM, J., Berek, J. S., & Bonavida, B. (1988). SENSITIVITY OF FRESH AND CULTURED OVARIAN TUMOR-CELLS TO TUMOR NECROSIS FACTOR, INTERFERON-ALPHA-2, AND OK-432. CANCER IMMUNOLOGY IMMUNOTHERAPY, 27(3), 246-254.

PREOPERATIVE EVALUATION OF SERUM CA-125 LEVELS IN PREMENOPAUSAL AND POSTMENOPAUSAL PATIENTS WITH PELVIC MASSES - DISCRIMINATION OF BENIGN FROM MALIGNANT DISEASE
Malkasian, G. D., Knapp, R. C., Lavin, P. T., Zurawski, V. R., Podratz, K. C., & RITTS, R. E. (1988). PREOPERATIVE EVALUATION OF SERUM CA-125 LEVELS IN PREMENOPAUSAL AND POSTMENOPAUSAL PATIENTS WITH PELVIC MASSES - DISCRIMINATION OF BENIGN FROM MALIGNANT DISEASE. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 159(2), 341-346.

IMMUNOLOGICAL CONTROL OF OVARIAN-CANCER
ZIGHELBOIM, J., Nio, Y., Berek, J. S., & Bonavida, B. (1988). IMMUNOLOGICAL CONTROL OF OVARIAN-CANCER. NATURAL IMMUNITY AND CELL GROWTH REGULATION, 7(4), 216-225.

Uterine corpus and cervical cancer.
Berek, J. S., Hacker, N. F., Hatch, K. D., & Young, R. C. (1988). Uterine corpus and cervical cancer. Current problems in cancer, 12(2), 61-131.

CONTROVERSIES IN THE MANAGEMENT OF CERVICAL ADENOCARCINOMA
Brand, E., Berek, J. S., & Hacker, N. F. (1988). CONTROVERSIES IN THE MANAGEMENT OF CERVICAL ADENOCARCINOMA. OBSTETRICS AND GYNECOLOGY, 71(2), 261-269.

Minimal cervical cancer: definition and histology.
Fu, Y. S., & Berek, J. S. (1988). Minimal cervical cancer: definition and histology. Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer, 106, 47-56.

INTRAPERITONEAL CISPLATINUM AS SALVAGE THERAPY FOR REFRACTORY EPITHELIAL OVARIAN-CANCER
Hacker, N. F., Berek, J. S., Pretorius, R. G., Zuckerman, J., Eisenkop, S., & Lagasse, L. D. (1987). INTRAPERITONEAL CISPLATINUM AS SALVAGE THERAPY FOR REFRACTORY EPITHELIAL OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 70(5), 759-764.

RHABDOMYOSARCOMA OF THE UTERINE CERVIX - SARCOMA BOTRYOIDES
Brand, E., Berek, J. S., Nieberg, R. K., & Hacker, N. F. (1987). RHABDOMYOSARCOMA OF THE UTERINE CERVIX - SARCOMA BOTRYOIDES. CANCER, 60(7), 1552-1560.

DISTANT METASTASES IN EPITHELIAL OVARIAN-CARCINOMA
Dauplat, J., Hacker, N. F., Nieberg, R. K., Berek, J. S., Rose, T. P., & Sagae, S. (1987). DISTANT METASTASES IN EPITHELIAL OVARIAN-CARCINOMA. CANCER, 60(7), 1561-1566.

PROGNOSTIC-SIGNIFICANCE OF DNA PLOIDY AND MORPHOMETRIC ANALYSES OF ADENOCARCINOMA OF THE UTERINE CERVIX
Fu, Y. S., Hall, T. L., Berek, J. S., Hacker, N. F., & Reagan, J. W. (1987). PROGNOSTIC-SIGNIFICANCE OF DNA PLOIDY AND MORPHOMETRIC ANALYSES OF ADENOCARCINOMA OF THE UTERINE CERVIX. ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY, 9(1), 17-24.

CA 125 FOR THE MONITORING OF OVARIAN-CARCINOMA DURING PRIMARY THERAPY
Lavin, P. T., Knapp, R. C., MALKASIAN, G., Whitney, C. W., BEREK, J. C., & Bast, R. C. (1987). CA 125 FOR THE MONITORING OF OVARIAN-CARCINOMA DURING PRIMARY THERAPY. OBSTETRICS AND GYNECOLOGY, 69(2), 223-227.

Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervix.
Fu, Y. S., Berek, J. S., & Hilborne, L. H. (1987). Diagnostic problems of in situ and invasive adenocarcinomas of the uterine cervix. Applied pathology, 5(1), 47-56.

HUMAN PAPILLOMAVIRUS DEOXYRIBONUCLEIC-ACID IN ADENOCARCINOMA AND ADENOSQUAMOUS CARCINOMA OF THE UTERINE CERVIX
Smotkin, D., Berek, J. S., Fu, Y. S., Hacker, N. F., Major, F. J., & WETTSTEIN, F. O. (1986). HUMAN PAPILLOMAVIRUS DEOXYRIBONUCLEIC-ACID IN ADENOCARCINOMA AND ADENOSQUAMOUS CARCINOMA OF THE UTERINE CERVIX. OBSTETRICS AND GYNECOLOGY, 68(2), 241-244.

THE CA 125 ASSAY AS A PREDICTOR OF CLINICAL RECURRENCE IN EPITHELIAL OVARIAN-CANCER
Niloff, J. M., Knapp, R. C., Lavin, P. T., Malkasian, G. D., Berek, J. S., & Bast, R. C. (1986). THE CA 125 ASSAY AS A PREDICTOR OF CLINICAL RECURRENCE IN EPITHELIAL OVARIAN-CANCER. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 155(1), 56-60.

CYTOREDUCTIVE SURGERY IN OVARIAN-CARCINOMA - FEASIBILITY AND MORBIDITY
Heintz, A. Pm., Hacker, N. F., Berek, J. S., Rose, T. P., Munoz, A. K., & Lagasse, L. D. (1986). CYTOREDUCTIVE SURGERY IN OVARIAN-CARCINOMA - FEASIBILITY AND MORBIDITY. OBSTETRICS AND GYNECOLOGY, 67(6), 783-788.

CA-125 SERUM LEVELS CORRELATED WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS
Berek, J. S., Knapp, R. C., Malkasian, G. D., Lavin, P. T., Whitney, C., & Bast, R. C. (1986). CA-125 SERUM LEVELS CORRELATED WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS. OBSTETRICS AND GYNECOLOGY, 67(5), 685-689.

NUCLEAR DEOXYRIBONUCLEIC-ACID HETEROGENEITY OF OVARIAN BORDERLINE MALIGNANT SEROUS TUMORS
Fu, Y. S., Ro, J., Reagan, J. W., Hall, T. L., & Berek, J. (1986). NUCLEAR DEOXYRIBONUCLEIC-ACID HETEROGENEITY OF OVARIAN BORDERLINE MALIGNANT SEROUS TUMORS. OBSTETRICS AND GYNECOLOGY, 67(4), 478-482.

PHASE-II TRIAL OF CISPLATIN IN ADVANCED OR RECURRENT CANCER OF THE VAGINA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
Thigpen, J. T., Blessing, J. A., Homesley, H. D., Berek, J. S., & Creasman, W. T. (1986). PHASE-II TRIAL OF CISPLATIN IN ADVANCED OR RECURRENT CANCER OF THE VAGINA - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. GYNECOLOGIC ONCOLOGY, 23(1), 101-104.

ANTITUMOR AND IMMUNOLOGICAL EFFECTS OF A PYRIDINE-EXTRACTED FRACTION OF PROPIONIBACTERIUM-ACNES
Lichtenstein, A., & Berek, J. (1986). ANTITUMOR AND IMMUNOLOGICAL EFFECTS OF A PYRIDINE-EXTRACTED FRACTION OF PROPIONIBACTERIUM-ACNES. CANCER IMMUNOLOGY IMMUNOTHERAPY, 22(1), 24-30.

Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer.
Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., & Lagasse, L. D. (1985). Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer. Cancer treatment reviews, 12, 23-32.

SYNERGISTIC EFFECTS OF COMBINATION SEQUENTIAL IMMUNOTHERAPIES IN A MURINE OVARIAN-CANCER MODEL
Berek, J. S., Lichtenstein, A. K., Knox, R. M., Jung, T. S., Rose, T. P., & ZIGHELBOIM, J. (1985). SYNERGISTIC EFFECTS OF COMBINATION SEQUENTIAL IMMUNOTHERAPIES IN A MURINE OVARIAN-CANCER MODEL. CANCER RESEARCH, 45(9), 4215-4218.

INTRAPERITONEAL IMMUNOTHERAPY OF EPITHELIAL OVARIAN-CARCINOMA WITH CORYNEBACTERIUM-PARVUM
Berek, J. S., Knapp, R. C., Hacker, N. F., Lichtenstein, A., Jung, T., & Bast, R. C. (1985). INTRAPERITONEAL IMMUNOTHERAPY OF EPITHELIAL OVARIAN-CARCINOMA WITH CORYNEBACTERIUM-PARVUM. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 152(8), 1003-1010.

WHOLE ABDOMINAL RADIATION AS SALVAGE THERAPY FOR EPITHELIAL OVARIAN-CANCER
Hacker, N. F., Berek, J. S., Burnison, C. M., Heintz, A. Pm., Juillard, G. Jf., & Lagasse, L. D. (1985). WHOLE ABDOMINAL RADIATION AS SALVAGE THERAPY FOR EPITHELIAL OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 65(1), 60-66.

INTRAPERITONEAL RECOMBINANT ALPHA-INTERFERON FOR SALVAGE IMMUNOTHERAPY IN STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY
Berek, J. S., Hacker, N. F., Lichtenstein, A., Jung, T., Spina, C., & ZIGHELBOIM, J. (1985). INTRAPERITONEAL RECOMBINANT ALPHA-INTERFERON FOR SALVAGE IMMUNOTHERAPY IN STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY. CANCER RESEARCH, 45(9), 4447-4453.

ADENOCARCINOMA OF THE UTERINE CERVIX - HISTOLOGIC VARIABLES ASSOCIATED WITH LYMPH-NODE METASTASIS AND SURVIVAL
Berek, J. S., Hacker, N. F., Fu, Y. S., SOKALE, J. R., LEUCHTER, R. C., & Lagasse, L. D. (1985). ADENOCARCINOMA OF THE UTERINE CERVIX - HISTOLOGIC VARIABLES ASSOCIATED WITH LYMPH-NODE METASTASIS AND SURVIVAL. OBSTETRICS AND GYNECOLOGY, 65(1), 46-52.

NATURAL-KILLER INHIBITORY SUBSTANCE PRODUCED BY THE PERITONEAL-CELLS OF PATIENTS WITH OVARIAN-CANCER
Lichtenstein, A. K., Berek, J., & ZIGHELBOIM, J. (1985). NATURAL-KILLER INHIBITORY SUBSTANCE PRODUCED BY THE PERITONEAL-CELLS OF PATIENTS WITH OVARIAN-CANCER. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 74(2), 349-355.

ROLE OF INFLAMMATORY NEUTROPHILS IN ANTITUMOR EFFECTS INDUCED BY INTRAPERITONEAL ADMINISTRATION OF CORYNEBACTERIUM-PARVUM IN MICE
Lichtenstein, A. K., Berek, J., Kahle, J., & ZIGHELBOIM, J. (1984). ROLE OF INFLAMMATORY NEUTROPHILS IN ANTITUMOR EFFECTS INDUCED BY INTRAPERITONEAL ADMINISTRATION OF CORYNEBACTERIUM-PARVUM IN MICE. CANCER RESEARCH, 44(11), 5118-5123.

SUCCESSFUL IMMUNOTHERAPY WITH INTRAPERITONEAL CORNYEBACTERIUM-PARVUM IN A MURINE OVARIAN-CANCER MODEL IS ASSOCIATED WITH THE RECRUITMENT OF TUMOR-LYTIC NEUTROPHILS INTO THE PERITONEAL-CAVITY
Lichtenstein, A. K., Kahle, J., Berek, J., & ZIGHELBOIM, J. (1984). SUCCESSFUL IMMUNOTHERAPY WITH INTRAPERITONEAL CORNYEBACTERIUM-PARVUM IN A MURINE OVARIAN-CANCER MODEL IS ASSOCIATED WITH THE RECRUITMENT OF TUMOR-LYTIC NEUTROPHILS INTO THE PERITONEAL-CAVITY. JOURNAL OF IMMUNOLOGY, 133(1), 519-526.

INDIVIDUALIZATION OF TREATMENT FOR STAGE-I SQUAMOUS-CELL VULVAR CARCINOMA
Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., & Leuchter, R. S. (1984). INDIVIDUALIZATION OF TREATMENT FOR STAGE-I SQUAMOUS-CELL VULVAR CARCINOMA. OBSTETRICS AND GYNECOLOGY, 63(2), 155-162.

PREOPERATIVE RADIATION-THERAPY FOR LOCALLY ADVANCED VULVAR CANCER
Hacker, N. F., Berek, J. S., Juillard, G. Jf., & Lagasse, L. D. (1984). PREOPERATIVE RADIATION-THERAPY FOR LOCALLY ADVANCED VULVAR CANCER. CANCER, 54(10), 2056-2061.

IMMUNOTHERAPY WITH BIOCHEMICALLY DISSOCIATED FRACTIONS OF PROPIONIBACTERIUM ACNES IN A MURINE OVARIAN-CANCER MODEL
Berek, J. S., Cantrell, J. L., Lichtenstein, A. K., Hacker, N. F., Knox, R. M., & ZIGHELBOIM, J. (1984). IMMUNOTHERAPY WITH BIOCHEMICALLY DISSOCIATED FRACTIONS OF PROPIONIBACTERIUM ACNES IN A MURINE OVARIAN-CANCER MODEL. CANCER RESEARCH, 44(5), 1871-1875.

2ND-LOOK LAPAROTOMY IN STAGE-III EPITHELIAL OVARIAN-CANCER - CLINICAL-VARIABLES ASSOCIATED WITH DISEASE STATUS
Berek, J. S., Hacker, N. F., Lagasse, L. D., Poth, T., Resnick, B., & Nieberg, R. K. (1984). 2ND-LOOK LAPAROTOMY IN STAGE-III EPITHELIAL OVARIAN-CANCER - CLINICAL-VARIABLES ASSOCIATED WITH DISEASE STATUS. OBSTETRICS AND GYNECOLOGY, 64(2), 207-212.

RECTOSIGMOID COLECTOMY AND REANASTOMOSIS TO FACILITATE RESECTION OF PRIMARY AND RECURRENT GYNECOLOGIC CANCER
Berek, J. S., Hacker, N. F., & Lagasse, L. D. (1984). RECTOSIGMOID COLECTOMY AND REANASTOMOSIS TO FACILITATE RESECTION OF PRIMARY AND RECURRENT GYNECOLOGIC CANCER. OBSTETRICS AND GYNECOLOGY, 64(5), 715-720.

VAGINAL RECONSTRUCTION PERFORMED SIMULTANEOUSLY WITH PELVIC EXENTERATION
Berek, J. S., Hacker, N. F., & Lagasse, L. D. (1984). VAGINAL RECONSTRUCTION PERFORMED SIMULTANEOUSLY WITH PELVIC EXENTERATION. OBSTETRICS AND GYNECOLOGY, 63(3), 318-323.

LYMPHOCYTE CYTO-TOXICITY IN THE PERITONEAL-CAVITY AND BLOOD OF PATIENTS WITH OVARIAN-CANCER
Berek, J. S., Bast, R. C., Lichtenstein, A., Hacker, N. F., Spina, C. A., & ZIGHELBOIM, J. (1984). LYMPHOCYTE CYTO-TOXICITY IN THE PERITONEAL-CAVITY AND BLOOD OF PATIENTS WITH OVARIAN-CANCER. OBSTETRICS AND GYNECOLOGY, 64(5), 708-714.

ACTIVATION OF PERITONEAL LYMPHOCYTE CYTO-TOXICITY IN PATIENTS WITH OVARIAN-CANCER BY INTRAPERITONEAL TREATMENT WITH CORYNEBACTERIUM-PARVUM
Lichtenstein, A., Berek, J., Bast, R., Spina, C., Hacker, N., & ZIGHELBOIM, J. (1984). ACTIVATION OF PERITONEAL LYMPHOCYTE CYTO-TOXICITY IN PATIENTS WITH OVARIAN-CANCER BY INTRAPERITONEAL TREATMENT WITH CORYNEBACTERIUM-PARVUM. JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 3(4), 371-378.

ESTROGEN AND PROGESTERONE RECEPTORS IN OVARIAN NEOPLASMS
Ford, L. C., Berek, J. S., Lagasse, L. D., Hacker, N. F., Heins, Y., & DELANGE, R. J. (1983). ESTROGEN AND PROGESTERONE RECEPTORS IN OVARIAN NEOPLASMS. GYNECOLOGIC ONCOLOGY, 15(3), 299-304.

DELAYED VAGINAL RECONSTRUCTION IN THE FIBROTIC PELVIS FOLLOWING RADIATION OR PREVIOUS RECONSTRUCTION
Berek, J. S., Hacker, N. F., Lagasse, L. D., & Smith, M. L. (1983). DELAYED VAGINAL RECONSTRUCTION IN THE FIBROTIC PELVIS FOLLOWING RADIATION OR PREVIOUS RECONSTRUCTION. OBSTETRICS AND GYNECOLOGY, 61(6), 743-748.

MICROINVASIVE CARCINOMA OF THE VULVA
Hacker, N. F., Berek, J. S., Lagasse, L. D., & Nieberg, R. K. (1983). MICROINVASIVE CARCINOMA OF THE VULVA. OBSTETRICS AND GYNECOLOGY, 62(1), 134-135.

LAPAROSCOPY IN THE MANAGEMENT OF PATIENTS WITH OVARIAN-CARCINOMA
Berek, J. S., & Hacker, N. F. (1983). LAPAROSCOPY IN THE MANAGEMENT OF PATIENTS WITH OVARIAN-CARCINOMA. CLINICS IN OBSTETRICS AND GYNAECOLOGY, 10(2), 213-222.

PHARMACOKINETICS OF IP CISPLATIN IN REFRACTORY OVARIAN-CARCINOMA
Pretorius, R. G., Hacker, N. F., Berek, J. S., Ford, L. C., Hoeschele, J. D., & Lagasse, L. D. (1983). PHARMACOKINETICS OF IP CISPLATIN IN REFRACTORY OVARIAN-CARCINOMA. CANCER TREATMENT REPORTS, 67(12), 1085-1092.